Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031957 | 1.00 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL401725 | 1.00 | KMT2A (0.67) | KMT2AEPHX2FABP5FABP7CA1 | |
| Hydrochloric Acid SCHEMBL1595146 | 0.98 | KMT2A (0.65) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL27640993 | 0.88 | KMT2A (0.57) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL21332462 | 0.86 | KMT2A (0.66) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL18510206 | 0.85 | KMT2A (0.61) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL30238049 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1800381 | 0.85 | KMT2A (0.64) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL25612527 | 0.84 | KMT2A (0.68) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1105520 | 0.84 | KMT2A (0.63) | KMT2AEPHX2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | disclosed |
| US-12630601-B2 | Process for preparing a GIP/GLP1 dual agonist | ELI LILLY AND COMPANY (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122036701-A | Responsive near infrared one-region fluorescent compound and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12624064-B2 | Linker molecule and use thereof in methods for purifying peptides | Gyros Protein Technologies AB (SE) | 2026-05-12 | — | — | US | disclosed |
| US-12624079-B2 | Process for preparing a GIP/GLP1 dual agonist | ELI LILLY AND COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | BAR ILAN UNIVERSITY (IL) | 2026-05-05 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4685157-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685156-A2 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | Eli Lilly and Company (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2023097407-A1 | MODIFIED AMATOXINS AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-06-08 | — | — | WO | disclosed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | disclosed |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-29 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | disclosed |
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | ELI LILLY AND COMPANY | 2022-05-05 | — | — | US | disclosed |
| WO-2022054062-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | BAR ILAN UNIVERSITY (IL) | 2022-03-17 | — | — | WO | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-113999289-A | Preparation method of goserelin | 杭州信海医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | KMT2A 1523/4885EPHX2 2881/4885FABP5 1137/4885 |
| US-12624079-B2 | Process for preparing a GIP/GLP1 dual agonist | GLP1R, GIPR, GPR119 | KMT2A 953/4885EPHX2 3646/4885FABP5 3546/4885 |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | TPX2, IAPP, HAX1 | KMT2A 2546/4885EPHX2 2136/4885FABP5 2277/4885 |
| US-12630601-B2 | Process for preparing a GIP/GLP1 dual agonist | GLP1R, GIPR, IAPP | KMT2A 633/4885EPHX2 3203/4885FABP5 4570/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | KMT2A 2773/4885EPHX2 2419/4885FABP5 666/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | KMT2A 1523/4885EPHX2 2881/4885FABP5 1137/4885 |
| US-20220135639-A1 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | GLP1R, GIPR, GPR119 | KMT2A 2749/4885EPHX2 2562/4885FABP5 2754/4885 |
| US-12624064-B2 | Linker molecule and use thereof in methods for purifying peptides | SPPL2B, SPPL2A, VIP | KMT2A 4464/4885EPHX2 1193/4885FABP5 3278/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | KMT2A 2188/4885EPHX2 3200/4885FABP5 2296/4885 |
| US-20220306577-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | KMT2A 1523/4885EPHX2 2881/4885FABP5 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.